Loading...
•
Sep 30, 2024
Ocular Therapeutix Q3 2024 Earnings Report
Ocular Therapeutix reported its Q3 2024 financial results and business highlights.
Key Takeaways
Ocular Therapeutix reported a total net revenue of $15.4 million for the third quarter of 2024, a 2.3% increase over the comparable period in 2023. The company's cash and cash equivalents were $427.2 million as of September 30, 2024, which is expected to fund operations into 2028. The company expects full-year 2024 total net revenues for DEXTENZA to be between $62.0 million and $67.0 million, compared to $57.9 million reported for 2023.
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025.
Active clinical trial sites now enrolling patients directly into SOL-R.
Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028.
Total net revenue was $15.4 million for the third quarter of 2024, a 2.3% increase over the comparable period in 2023.
Ocular Therapeutix
Ocular Therapeutix
Forward Guidance
The Company expects full-year 2024 total net revenues for DEXTENZA to be between $62.0 million and $67.0 million, compared to $57.9 million reported for 2023.